Advances in Antibody Design.

The use of monoclonal antibodies as therapeutics requires optimizing several of their key attributes. These include binding affinity and specificity, folding stability, solubility, pharmacokinetics, effector functions, and compatibility with the attachment of additional antibody domains (bispecific antibodies) and cytotoxic drugs (antibody-drug conjugates). Addressing these and other challenges requires the use of systematic design methods that complement powerful immunization and in vitro screening methods. We review advances in designing the binding loops, scaffolds, domain interfaces, constant regions, post-translational and chemical modifications, and bispecific architectures of antibodies and fragments thereof to improve their bioactivity. We also highlight unmet challenges in antibody design that must be overcome to generate potent antibody therapeutics.

[1]  K. Shitara,et al.  Engineered anti‐CD20 antibodies with enhanced complement‐activating capacity mediate potent anti‐lymphoma activity , 2009, Cancer science.

[2]  M. Dorywalska,et al.  Location matters: site of conjugation modulates stability and pharmacokinetics of antibody drug conjugates. , 2013, Chemistry & biology.

[3]  C. Barbas,et al.  Building synthetic antibodies as adhesive ligands for integrins. , 1994, The Journal of biological chemistry.

[4]  Camellia W. Adams,et al.  An efficient route to human bispecific IgG , 1998, Nature Biotechnology.

[5]  R. Williamson,et al.  Toward Molecular Dissection of PrPC-PrPSc Interactions* , 2007, Journal of Biological Chemistry.

[6]  Bruce Tidor,et al.  Aglycosylated immunoglobulin G1 variants productively engage activating Fc receptors , 2008, Proceedings of the National Academy of Sciences.

[7]  P. Senter Potent antibody drug conjugates for cancer therapy. , 2009, Current opinion in chemical biology.

[8]  J W Smith,et al.  High-affinity self-reactive human antibodies by design and selection: targeting the integrin ligand binding site. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[9]  Y. Duan,et al.  Probing the stability-limiting regions of an antibody single-chain variable fragment: a molecular dynamics simulation study. , 2011, Protein engineering, design & selection : PEDS.

[10]  T. Hofer,et al.  Molecularly defined antibody conjugation through a selenocysteine interface. , 2009, Biochemistry.

[11]  D. Röthlisberger,et al.  Domain interactions in the Fab fragment: a comparative evaluation of the single-chain Fv and Fab format engineered with variable domains of different stability. , 2005, Journal of molecular biology.

[12]  Haruki Nakamura,et al.  Computer-aided antibody design , 2012, Protein engineering, design & selection : PEDS.

[13]  G. Winter,et al.  Aggregation-resistant domain antibodies selected on phage by heat denaturation , 2004, Nature Biotechnology.

[14]  Peter G Schultz,et al.  Synthesis of site-specific antibody-drug conjugates using unnatural amino acids , 2012, Proceedings of the National Academy of Sciences.

[15]  L. Presta,et al.  Engineered Antibodies with Increased Activity to Recruit Complement , 2001, The Journal of Immunology.

[16]  Sandeep Kumar,et al.  Insights into the potential aggregation liabilities of the b12 Fab fragment via elevated temperature molecular dynamics. , 2013, Protein engineering, design & selection : PEDS.

[17]  P. Tessier,et al.  Structure-based design of conformation- and sequence-specific antibodies against amyloid β , 2011, Proceedings of the National Academy of Sciences.

[18]  Zhen-ping Zhu,et al.  An efficient route to the production of an IgG-like bispecific antibody. , 2000, Protein engineering.

[19]  Damon L. Meyer,et al.  Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate , 2004, Clinical Cancer Research.

[20]  D. Burton,et al.  Motif-grafted antibodies containing the replicative interface of cellular PrP are specific for PrPSc. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[21]  C. J. Bond,et al.  Comprehensive Analysis of the Factors Contributing to the Stability and Solubility of Autonomous Human VH Domains* , 2008, Journal of Biological Chemistry.

[22]  Bruce Tidor,et al.  Computational design of antibody-affinity improvement beyond in vivo maturation , 2007, Nature Biotechnology.

[23]  Bernhardt L. Trout,et al.  Design of therapeutic proteins with enhanced stability , 2009, Proceedings of the National Academy of Sciences.

[24]  John McCafferty,et al.  Beyond natural antibodies: the power of in vitro display technologies , 2011, Nature Biotechnology.

[25]  L. Presta,et al.  'Knobs-into-holes' engineering of antibody CH3 domains for heavy chain heterodimerization. , 1996, Protein engineering.

[26]  Peter D. Senter,et al.  Development of potent monoclonal antibody auristatin conjugates for cancer therapy , 2003 .

[27]  Andreas Plückthun,et al.  Structure-based improvement of the biophysical properties of immunoglobulin VH domains with a generalizable approach. , 2003, Biochemistry.

[28]  P. M. Buck,et al.  Impact of deglycosylation and thermal stress on conformational stability of a full length murine igG2a monoclonal antibody: Observations from molecular dynamics simulations , 2013, Proteins.

[29]  Janice M. Reichert,et al.  Which are the antibodies to watch in 2013? , 2013, mAbs.

[30]  G. A. Lazar,et al.  Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions , 2010, mAbs.

[31]  Ian Kimber,et al.  Immunogenicity of therapeutic proteins: Influence of aggregation , 2013, Journal of immunotoxicology.

[32]  I. Sandlie,et al.  Chimeric mouse human IgG3 antibodies with an IgG4‐like hinge region induce complement‐mediated lysis more efficiently than IgG3 with normal hing , 1991, European journal of immunology.

[33]  JonathanSMARVIN,et al.  Recombinant approaches to IgG-like bispecific antibodies , 2005 .

[34]  R. Vessella,et al.  Engineering the isoelectric point of a renal cell carcinoma targeting antibody greatly enhances scFv solubility. , 1998, Immunotechnology : an international journal of immunological engineering.

[35]  L. Croner,et al.  Stability engineering of scFvs for the development of bispecific and multivalent antibodies. , 2010, Protein engineering, design & selection : PEDS.

[36]  G. Winter,et al.  Towards the design of an antibody that recognises a given protein epitope. , 1999, Journal of molecular biology.

[37]  T. Huynh,et al.  Free-energy simulations reveal that both hydrophobic and polar interactions are important for influenza hemagglutinin antibody binding. , 2012, Biophysical journal.

[38]  R. Jefferis,et al.  Recombinant antibody therapeutics: the impact of glycosylation on mechanisms of action. , 2009, Trends in pharmacological sciences.

[39]  S. Morrison,et al.  The binding affinity of human IgG for its high affinity Fc receptor is determined by multiple amino acids in the CH2 domain and is modulated by the hinge region , 1991, The Journal of experimental medicine.

[40]  Pavel Strop,et al.  Generating bispecific human IgG1 and IgG2 antibodies from any antibody pair. , 2012, Journal of molecular biology.

[41]  L. Jermutus,et al.  Aggregation, stability, and formulation of human antibody therapeutics. , 2011, Advances in protein chemistry and structural biology.

[42]  Richard D. Leapman,et al.  Self-Propagating, Molecular-Level Polymorphism in Alzheimer's ß-Amyloid Fibrils , 2005, Science.

[43]  G. A. Lazar,et al.  Modulation of antibody effector function. , 2011, Experimental cell research.

[44]  P. Tessier,et al.  Toward aggregation-resistant antibodies by design. , 2013, Trends in biotechnology.

[45]  C. Klein,et al.  Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. , 2010, Blood.

[46]  Sandeep Yadav,et al.  Weak interactions govern the viscosity of concentrated antibody solutions: high-throughput analysis using the diffusion interaction parameter. , 2012, Biophysical journal.

[47]  W. DeGrado,et al.  Nature-inspired design of motif-specific antibody scaffolds , 2013, Nature Biotechnology.

[48]  Zhen-ping Zhu,et al.  Single Variable Domain-IgG Fusion , 2006, Journal of Biological Chemistry.

[49]  G. Gilliland,et al.  Structure-based engineering of a monoclonal antibody for improved solubility. , 2010, Protein engineering, design & selection : PEDS.

[50]  Christilyn P. Graff,et al.  A stable IgG-like bispecific antibody targeting the epidermal growth factor receptor and the type I insulin-like growth factor receptor demonstrates superior anti-tumor activity , 2011, mAbs.

[51]  B. Schoeberl,et al.  Rapid optimization and prototyping for therapeutic antibody-like molecules , 2013, mAbs.

[52]  Timothy A. Whitehead,et al.  Computational Design of Proteins Targeting the Conserved Stem Region of Influenza Hemagglutinin , 2011, Science.

[53]  Paul Polakis,et al.  Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index , 2008, Nature Biotechnology.

[54]  David Baker,et al.  Macromolecular modeling with rosetta. , 2008, Annual review of biochemistry.

[55]  J. Tanha,et al.  Disulfide linkage engineering for improving biophysical properties of human VH domains. , 2012, Protein engineering, design & selection : PEDS.

[56]  Gideon Schreiber,et al.  Rational design of faster associating and tighter binding protein complexes , 2000, Nature Structural Biology.

[57]  J. Tanha,et al.  Aggregation-resistant VHs selected by in vitro evolution tend to have disulfide-bonded loops and acidic isoelectric points. , 2008, Protein engineering, design & selection : PEDS.

[58]  Tomoaki Nakagawa,et al.  Engineered antibodies of IgG1/IgG3 mixed isotype with enhanced cytotoxic activities. , 2008, Cancer research.

[59]  M. Taussig,et al.  Phospho-specific antibodies by design , 2013, Nature Biotechnology.

[60]  Yoshiki Yamaguchi,et al.  Structural comparison of fucosylated and nonfucosylated Fc fragments of human immunoglobulin G1. , 2007, Journal of molecular biology.

[61]  Jennifer B. Webster,et al.  Engineered antibody-drug conjugates with defined sites and stoichiometries of drug attachment. , 2006, Protein engineering, design & selection : PEDS.

[62]  J. Baenziger,et al.  Thermal stabilization of a single‐chain Fv antibody fragment by introduction of a disulphide bond , 1995, FEBS letters.

[63]  Wolfgang Schaefer,et al.  Progress in overcoming the chain association issue in bispecific heterodimeric IgG antibodies , 2012, mAbs.

[64]  J. Haidar,et al.  A universal combinatorial design of antibody framework to graft distinct CDR sequences: A bioinformatics approach , 2012, Proteins.

[65]  Diego Ellerman,et al.  Bispecific antibodies with natural architecture produced by co-culture of bacteria expressing two distinct half-antibodies , 2013, Nature Biotechnology.

[66]  Brian Kuhlman,et al.  Structure-based design of supercharged, highly thermoresistant antibodies. , 2012, Chemistry & biology.

[67]  S. Morrison,et al.  The differential ability of human IgG1 and IgG4 to activate complement is determined by the COOH-terminal sequence of the CH2 domain , 1991, The Journal of experimental medicine.

[68]  Bernhardt L Trout,et al.  Glycosylation influences on the aggregation propensity of therapeutic monoclonal antibodies. , 2011, Biotechnology journal.

[69]  R. Chari,et al.  Antibody-drug conjugates: an emerging concept in cancer therapy. , 2014, Angewandte Chemie.

[70]  M. Sliwkowski,et al.  Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates , 2012, Nature Biotechnology.

[71]  L. Presta,et al.  Lack of Fucose on Human IgG1 N-Linked Oligosaccharide Improves Binding to Human FcγRIII and Antibody-dependent Cellular Toxicity* , 2002, The Journal of Biological Chemistry.

[72]  S. Thierfelder,et al.  Preferential species-restricted heavy/light chain pairing in rat/mouse quadromas. Implications for a single-step purification of bispecific antibodies. , 1995, Journal of immunology.

[73]  K Dane Wittrup,et al.  A modular IgG-scFv bispecific antibody topology. , 2010, Protein engineering, design & selection : PEDS.

[74]  T. Ghayur,et al.  Molecular construction and optimization of anti-human IL-1α/β dual variable domain immunoglobulin (DVD-IgTM) molecules , 2009 .

[75]  Brian Kuhlman,et al.  Computational design of a symmetric homodimer using β-strand assembly , 2011, Proceedings of the National Academy of Sciences.

[76]  M. Honer,et al.  Site-specific and stoichiometric modification of antibodies by bacterial transglutaminase. , 2010, Angewandte Chemie.

[77]  Andreas Plückthun,et al.  Stability improvement of antibodies for extracellular and intracellular applications: CDR grafting to stable frameworks and structure-based framework engineering. , 2004, Methods.

[78]  Robert Huber,et al.  The 3.2-Å crystal structure of the human IgG1 Fc fragment–FcγRIII complex , 2000, Nature.

[79]  Luke N Robinson,et al.  Redesign of a cross-reactive antibody to dengue virus with broad-spectrum activity and increased in vivo potency , 2013, Proceedings of the National Academy of Sciences.

[80]  I. Pastan,et al.  Engineering interchain disulfide bonds into conserved framework regions of Fv fragments: improved biochemical characteristics of recombinant immunotoxins containing disulfide-stabilized Fv. , 1994, Protein engineering.

[81]  Haruki Nakamura,et al.  High‐resolution modeling of antibody structures by a combination of bioinformatics, expert knowledge, and molecular simulations , 2014, Proteins.

[82]  Guohui Li,et al.  Structural understanding of stabilization patterns in engineered bispecific Ig‐like antibody molecules , 2009, Proteins.

[83]  D. Gitlin Current aspects of the structure, function, and genetics of the immunoglobulins. , 1966, Annual Review of Medicine.

[84]  M. Wittekind,et al.  Enhancing Antibody Fc Heterodimer Formation through Electrostatic Steering Effects , 2010, The Journal of Biological Chemistry.

[85]  Leonard G. Presta,et al.  Mapping of the C1q Binding Site on Rituxan, a Chimeric Antibody with a Human IgG1 Fc , 2000, The Journal of Immunology.

[86]  A. Fersht,et al.  Rapid, electrostatically assisted association of proteins , 1996, Nature Structural Biology.

[87]  S. Jung,et al.  Aglycosylated IgG variants expressed in bacteria that selectively bind FcγRI potentiate tumor cell killing by monocyte-dendritic cells , 2009, Proceedings of the National Academy of Sciences.

[88]  Peter M Tessier,et al.  Optimal charged mutations in the complementarity-determining regions that prevent domain antibody aggregation are dependent on the antibody scaffold. , 2014, Protein engineering, design & selection : PEDS.

[89]  C. Ries,et al.  GA201 (RG7160): A Novel, Humanized, Glycoengineered Anti-EGFR Antibody with Enhanced ADCC and Superior In Vivo Efficacy Compared with Cetuximab , 2012, Clinical Cancer Research.

[90]  A. Plückthun,et al.  Biophysical properties of camelid V(HH) domains compared to those of human V(H)3 domains. , 2002, Biochemistry.

[91]  Brian D. Weitzner,et al.  Blind prediction performance of RosettaAntibody 3.0: Grafting, relaxation, kinematic loop modeling, and full CDR optimization , 2014, Proteins.

[92]  Jonathan S Marvin,et al.  Redesigning an antibody fragment for faster association with its antigen. , 2003, Biochemistry.

[93]  F. Heppner,et al.  Prevention of Scrapie Pathogenesis by Transgenic Expression of Anti-Prion Protein Antibodies , 2001, Science.

[94]  Leonard G. Presta,et al.  High Resolution Mapping of the Binding Site on Human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and Design of IgG1 Variants with Improved Binding to the FcγR* , 2001, The Journal of Biological Chemistry.

[95]  L. James,et al.  Crystal structure of HEL4, a soluble, refoldable human V(H) single domain with a germ-line scaffold. , 2004, Journal of molecular biology.

[96]  A. Plückthun,et al.  Engineering aggregation resistance in IgG by two independent mechanisms: lessons from comparison of Pichia pastoris and mammalian cell expression. , 2012, Journal of molecular biology.

[97]  John M Lambert,et al.  Structural characterization of the maytansinoid–monoclonal antibody immunoconjugate, huN901–DM1, by mass spectrometry , 2005, Protein science : a publication of the Protein Society.

[98]  Sahana Bose,et al.  Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin , 2007, Nature Biotechnology.

[99]  R. Wetzel,et al.  Destabilizing loop swaps in the CDRs of an immunoglobulin VL domain , 1995, Protein science : a publication of the Protein Society.

[100]  Paul Polakis,et al.  Site-specific antibody drug conjugates for cancer therapy , 2013, mAbs.

[101]  L. Presta,et al.  Remodeling domain interfaces to enhance heterodimer formation , 1997, Protein science : a publication of the Protein Society.

[102]  S. Muyldermans,et al.  Disulfide bond introduction for general stabilization of immunoglobulin heavy-chain variable domains. , 2008, Journal of molecular biology.

[103]  Bernhardt L Trout,et al.  Developability index: a rapid in silico tool for the screening of antibody aggregation propensity. , 2012, Journal of pharmaceutical sciences.

[104]  Costas D. Maranas,et al.  OptMAVEn – A New Framework for the de novo Design of Antibody Variable Region Models Targeting Specific Antigen Epitopes , 2014, PloS one.

[105]  Woody Sherman,et al.  Affinity enhancement of an in vivo matured therapeutic antibody using structure‐based computational design , 2006, Protein science : a publication of the Protein Society.

[106]  S. Kadono,et al.  Novel asymmetrically engineered antibody Fc variant with superior FcγR binding affinity and specificity compared with afucosylated Fc variant , 2013, mAbs.

[107]  Bernhardt L Trout,et al.  Computational methods to predict therapeutic protein aggregation. , 2012, Methods in molecular biology.

[108]  Kouhei Tsumoto,et al.  Affinity Improvement of a Therapeutic Antibody by Structure-Based Computational Design: Generation of Electrostatic Interactions in the Transition State Stabilizes the Antibody-Antigen Complex , 2014, PloS one.

[109]  W. Strohl,et al.  Optimization of Fc-mediated effector functions of monoclonal antibodies. , 2009, Current opinion in biotechnology.

[110]  A. Honegger,et al.  Engineering antibodies for stability and efficient folding. , 2008, Handbook of experimental pharmacology.

[111]  P. Tessier,et al.  Aggregation-resistant domain antibodies engineered with charged mutations near the edges of the complementarity-determining regions. , 2012, Protein engineering, design & selection : PEDS.

[112]  Pauline M. Rudd,et al.  Antibodies inhibit prion propagation and clear cell cultures of prion infectivity , 2001, Nature.

[113]  Hugues Bedouelle,et al.  Improving the stability of an antibody variable fragment by a combination of knowledge-based approaches: validation and mechanisms. , 2006, Journal of molecular biology.

[114]  K. Gunasekaran,et al.  Asymmetrical Fc Engineering Greatly Enhances Antibody-dependent Cellular Cytotoxicity (ADCC) Effector Function and Stability of the Modified Antibodies* , 2013, The Journal of Biological Chemistry.

[115]  Michael M C Sun,et al.  Reduction-alkylation strategies for the modification of specific monoclonal antibody disulfides. , 2005, Bioconjugate chemistry.

[116]  Herren Wu,et al.  Modulation of the Effector Functions of a Human IgG1 through Engineering of Its Hinge Region , 2006, The Journal of Immunology.

[117]  G. Frantz,et al.  Antibody-drug conjugates for the treatment of non-Hodgkin's lymphoma: target and linker-drug selection. , 2009, Cancer research.

[118]  B. Nolting Linker technologies for antibody-drug conjugates. , 2013, Methods in molecular biology.

[119]  Andrew Leaver-Fay,et al.  Generation of bispecific IgG antibodies by structure-based design of an orthogonal Fab interface , 2014, Nature Biotechnology.

[120]  A. Plückthun,et al.  Stability engineering of antibody single-chain Fv fragments. , 2001, Journal of molecular biology.

[121]  J. Wells,et al.  Stable heterodimers from remodeling the domain interface of a homodimer using a phage display library. , 1997, Journal of molecular biology.

[122]  S. Morrison,et al.  Design and production of novel tetravalent bispecific antibodies , 1997, Nature Biotechnology.

[123]  T. Raju,et al.  Terminal sugars of Fc glycans influence antibody effector functions of IgGs. , 2008, Current opinion in immunology.

[124]  G. Winter,et al.  Engineering bispecific antibodies. , 1993, Current opinion in biotechnology.

[125]  B. Sandmaier,et al.  Contributions of a highly conserved VH/VL hydrogen bonding interaction to scFv folding stability and refolding efficiency. , 1998, Biophysical journal.

[126]  D. Raleigh,et al.  Rational design of potent domain antibody inhibitors of amyloid fibril assembly , 2012, Proceedings of the National Academy of Sciences.

[127]  J. Ravetch,et al.  General mechanism for modulating immunoglobulin effector function , 2013, Proceedings of the National Academy of Sciences.

[128]  K. Shitara,et al.  Engineered therapeutic antibodies with improved effector functions , 2009, Cancer science.

[129]  R. Scheller,et al.  Rapid identification of reactive cysteine residues for site-specific labeling of antibody-Fabs. , 2008, Journal of immunological methods.

[130]  Y. Kurosawa,et al.  Effects of substitutions of amino acids on the thermal stability of the Fv fragments of antibodies , 1994, FEBS letters.

[131]  L. Croner,et al.  Conserved amino acid networks involved in antibody variable domain interactions , 2009, Proteins.

[132]  P. Carter,et al.  Antibody-drug conjugates in cancer therapy. , 2013, Annual review of medicine.

[133]  T Prospero,et al.  "Diabodies": small bivalent and bispecific antibody fragments. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[134]  C D Maranas,et al.  OptCDR: a general computational method for the design of antibody complementarity determining regions for targeted epitope binding. , 2010, Protein engineering, design & selection : PEDS.

[135]  J. Tso,et al.  Formation of a bispecific antibody by the use of leucine zippers. , 1992, Journal of immunology.

[136]  D. James,et al.  Control of Recombinant Monoclonal Antibody Effector Functions by Fc N‐Glycan Remodeling in Vitro , 2005, Biotechnology progress.

[137]  Tyler Day,et al.  Ab initio structure prediction of the antibody hypervariable H3 loop , 2013, Proteins.

[138]  P. Wirtz,et al.  Intrabody construction and expression III: Engineering hyperstable VH domains , 2008, Protein science : a publication of the Protein Society.

[139]  Peter M Tessier,et al.  Mutational analysis of domain antibodies reveals aggregation hotspots within and near the complementarity determining regions , 2011, Proteins.

[140]  Bin Liu,et al.  Methods for site-specific drug conjugation to antibodies , 2013, mAbs.

[141]  P. Carter,et al.  Bispecific human IgG by design. , 2001, Journal of immunological methods.

[142]  E. Goldman,et al.  Contributions of the Complementarity Determining Regions to the Thermal Stability of a Single-Domain Antibody , 2013, PloS one.

[143]  J. Huston,et al.  SEEDbodies: fusion proteins based on strand-exchange engineered domain (SEED) CH3 heterodimers in an Fc analogue platform for asymmetric binders or immunofusions and bispecific antibodies. , 2010, Protein engineering, design & selection : PEDS.

[144]  G. A. Lazar,et al.  Engineered antibody Fc variants with enhanced effector function. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[145]  L. Silvian,et al.  Improving the solubility of anti‐LINGO‐1 monoclonal antibody Li33 by isotype switching and targeted mutagenesis , 2010, Protein science : a publication of the Protein Society.

[146]  Guy Georges,et al.  Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies , 2011, Proceedings of the National Academy of Sciences.

[147]  B. Ramakrishnan,et al.  Site specific conjugation of fluoroprobes to the remodeled Fc N-glycans of monoclonal antibodies using mutant glycosyltransferases: application for cell surface antigen detection. , 2009, Bioconjugate chemistry.

[148]  D. Stock,et al.  General strategy for the generation of human antibody variable domains with increased aggregation resistance , 2012, Proceedings of the National Academy of Sciences.

[149]  P. Tessier,et al.  Engineering aggregation-resistant antibodies. , 2012, Annual review of chemical and biomolecular engineering.

[150]  L. Simmons,et al.  Expression of full-length immunoglobulins in Escherichia coli: rapid and efficient production of aglycosylated antibodies. , 2002, Journal of immunological methods.